Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by US Bancorp DE

US Bancorp DE lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,812 shares of the company’s stock after acquiring an additional 656 shares during the period. US Bancorp DE’s holdings in Teva Pharmaceutical Industries were worth $166,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. Ion Asset Management Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after purchasing an additional 409,778 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 1.2% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock valued at $404,775,000 after purchasing an additional 300,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock valued at $338,989,000 after acquiring an additional 22,044,407 shares in the last quarter. Duquesne Family Office LLC grew its position in Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after acquiring an additional 7,569,450 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Teva Pharmaceutical Industries by 40.6% during the fourth quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company’s stock valued at $148,497,000 after purchasing an additional 1,945,688 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,001 shares of company stock valued at $996,958. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $17.86 on Friday. The company has a market cap of $20.48 billion, a P/E ratio of -111.63, a PEG ratio of 1.06 and a beta of 0.62. The stock has a fifty day moving average price of $16.69 and a 200 day moving average price of $16.25. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The company had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. During the same quarter in the prior year, the business posted $0.61 earnings per share. The company’s revenue for the quarter was up .3% compared to the same quarter last year. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Finally, Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.